Tectonic Therapeutic (TECX) Price & Analysis

Compare

594 Followers

TECX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.70 - $61.07

Previous CloseN/A

Volume30.18K

Average Volume (3M)626.70K

Market Cap

$299.77M

Enterprise Value$85.73M

Total Cash (Recent Filing)$287.38M

Total Debt (Recent Filing)$1.94M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Nov 06, 2025

EPS Estimate

-1.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.07

Shares Outstanding18,712,128

10 Day Avg. Volume518,831

30 Day Avg. Volume626,701

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.29

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-52.53

Enterprise Value/Ebitda-1.28

Forecast

1Y Price Target

$83.40

Price Target Upside420.60% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Enrollment StrategyTECX's enrollment strategy for relaxin trials differs meaningfully from the failed volenrelaxin trial by LLY, suggesting potential for different outcomes.

Financial PositionTectonic ended the quarter with a cash position of $306.2M, which is expected to support operations into 4Q28.

Potential Market ExpansionThe expansion into PH-ILD makes sense on multiple fronts and could significantly increase the value of shares.

Bears Say

Drug Development ConcernsThe failed volenrelaxin trial casts a cloud over relaxin drug development, raising concerns about the entire drug class.

Market ReactionShares of TECX are off >30% following Eli Lilly's data presentation/publication from their failed recombinant long acting relaxin study.

Short InterestThe short interest in Tectonic Therapeutic stock is relatively high at 17.8% of the float.

Tectonic Therapeutic News

3 ‘Strong Buy’ Biotech Stocks Top Analysts Believe Have Over 300% Upside

Wall Street analysts don’t hand out “Strong Buy” ratings lightly. When they do, it usually means they’re convinced...

1M ago

CGEM

TECX

Optimistic Outlook on Tectonic Therapeutic: Strategic Trial Design and Upcoming Catalysts

Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating yesterday....

1M ago

TECX

Tectonic Therapeutic initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $80 price target The firm likes...

1M ago

TECX

Confidence in Tectonic Therapeutic’s Strategic Approach Amid Eli Lilly’s Trial Setback

Danielle Brill, an analyst from Truist Financial, maintained the Buy rating on Tectonic Therapeutic. The associated price target...

1M ago

TECX

Tectonic pullback on Eli Lilly relaxin data ‘overdone,’ says Truist

Truist analyst Danielle Brill notes that shares of Tectonic Therapeutic (TECX) are off by greater than 30% following...

1M ago

LLY

TECX

Tectonic Therapeutic’s Strategic Expansion and Financial Stability Justify Buy Rating

Leerink Partners analyst David Risinger reiterated a Buy rating on Tectonic Therapeutic yesterday and set a price target...

2M ago

TECX

Tectonic Therapeutic’s Strategic Advancements and Promising Pipeline Drive Buy Rating

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Tectonic Therapeutic,...

2M ago

TECX

Promising Outlook for Tectonic Therapeutic: Strategic Differentiation and Market Opportunities

Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating yesterday....

2M ago

TECX

Tectonic Therapeutic Inc. Reports Increased Cash Reserves

Tectonic Therapeutic Inc ( ($TECX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

TECX

Tectonic Therapeutic Reports Q2 Financial Results

The latest announcement is out from Tectonic Therapeutic ( ($TECX) ). On August 7, 2025, Tectonic Therapeutic announced...

2M ago

TECX

Tectonic Therapeutic initiated with a Buy at Truist

Truist initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $64 price target Tectonic is advancing...

3M ago

TECX

Closing Bell Movers: Merit Medical Systems gains after Q2 outlook

In the opening hour of the evening session, U.S. equity futures are down again following a post-holiday session...

3M ago

BIIB

MMSI

Tectonic Therapeutic files $400M mixed securities shelf

17:50 EDT Tectonic Therapeutic (TECX) files $400M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

TECX

Tectonic Therapeutic joins Russell 3000 Index

Tectonic Therapeutic (TECX) announced that it has been added to the broad-market Russell 3000 Index. Tectonic’s addition follows...

4M ago

TECX

TECX FAQ

What was Tectonic Therapeutic’s price range in the past 12 months?

Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.

What is Tectonic Therapeutic’s market cap?

Tectonic Therapeutic’s market cap is $299.77M.

When is Tectonic Therapeutic’s upcoming earnings report date?

Tectonic Therapeutic’s upcoming earnings report date is Nov 06, 2025 which is in 23 days.

How were Tectonic Therapeutic’s earnings last quarter?

Tectonic Therapeutic released its earnings results on Aug 07, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.977 by -$0.093.

Is Tectonic Therapeutic overvalued?

According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tectonic Therapeutic pay dividends?

Tectonic Therapeutic does not currently pay dividends.

What is Tectonic Therapeutic’s EPS estimate?

Tectonic Therapeutic’s EPS estimate is -1.06.

How many shares outstanding does Tectonic Therapeutic have?

Tectonic Therapeutic has 18,712,128 shares outstanding.

What happened to Tectonic Therapeutic’s price movement after its last earnings report?

Tectonic Therapeutic reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.977. Following the earnings report the stock price went up 1.779%.

Which hedge fund is a major shareholder of Tectonic Therapeutic?

Currently, no hedge funds are holding shares in TECX

Tectonic Therapeutic Stock Smart Score

Neutral

Fundamentals

Return on Equity

-29.32%

Trailing 12-Months

Asset Growth

52.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tectonic Therapeutic

Tectonic Therapeutic (TECX) is a biotechnology company focused on discovering and developing novel therapeutics to treat complex diseases. The company operates primarily in the biopharmaceutical sector, leveraging cutting-edge technology and scientific research to create innovative drug candidates. Tectonic Therapeutic is committed to addressing unmet medical needs across various therapeutic areas, including oncology, immunology, and rare diseases.

Tectonic Therapeutic (TECX) Earnings & Revenues

Historic Earnings Reports

TECX Stock 12 Month Forecast

Average Price Target

$83.40

▲(420.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","36":"$36","58":"$58","80":"$80","102":"$102"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$83.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$64.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,36,58,80,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.66,22.224615384615383,28.78923076923077,35.35384615384615,41.91846153846154,48.48307692307692,55.0476923076923,61.612307692307695,68.17692307692307,74.74153846153847,81.30615384615385,87.87076923076923,94.4353846153846,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.66,20.87076923076923,26.081538461538464,31.292307692307695,36.503076923076925,41.713846153846156,46.92461538461539,52.13538461538462,57.346153846153854,62.556923076923084,67.76769230769231,72.97846153846154,78.18923076923078,{"y":83.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.66,19.37846153846154,23.096923076923076,26.815384615384616,30.533846153846156,34.252307692307696,37.970769230769235,41.689230769230775,45.407692307692315,49.126153846153855,52.844615384615395,56.563076923076935,60.28153846153846,{"y":64,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >